A new live oral cholera vaccine, Peru-15, was studied for safety, immunogenicity, and excretion in 2 groups of healthy volunteers. Twelve inpatient volunteers received freshly harvested vaccine in doses of either 10 7 or 10 9 cfu. Subsequently 50 outpatient volunteers received freeze-dried vaccine in doses of 10 8 or 10 9 cfu or placebo in a three-cell, double-masked, placebo-controlled trial. The strain was well tolerated at all dose levels, and it stimulated high levels of vibriocidal antibodies in most inpatient volunteers and in all outpatient volunteers. Although antitoxin responses were less frequent and of lower magnitude than the vibriocidal responses, antitoxin responses were seen in ú60% of the outpatient volunteers. About 60% of the volunteers excreted the vaccine in their feces; however, fecal excretion did not correlate with serologic responses. It is concluded that Peru-15 is a safe and immunogenic oral vaccine for cholera.
Cholera remains an important public health problem with moter, was inserted into the recA locus, yielding Peru-3. This insertion inactivated recA, causing Peru-3 to be defective in cases occurring in nearly all developing countries, including 21 countries in the Western Hemisphere [1] . While improved homologous DNA recombination. A nonmotile variant was isolated and designated Peru-15 [7] . water and sanitation may eventually control the transmission of Vibrio cholerae, development of an effective vaccine could Following initial studies by Kenner et al. [7] , Peru-15 was tested further at the Vaccine Testing Unit, Johns Hopkins Unibe extremely helpful in limiting morbidity and mortality from the disease. Both killed and live oral vaccines are being develversity. Since Peru-15 is a newly developed, live, oral vaccine strain, the first study was conducted in an inpatient unit, using oped for cholera [2 -5] , and each has attractive attributes. Among a group of mutant V. cholerae strains [6] , one promising a freshly prepared vaccine. The initial inpatient study was needed for careful monitoring of the volunteers and for deconlive oral vaccine candidate is Peru-15 [7] . Derived from an El Tor Inaba isolate, this new live oral vaccine is similar to the tamination of their stools before disposal. After safety and stability of the vaccine in inpatient volunteers was demoncurrent pandemic strain.
Peru-15 has several defined genetic mutations that contribute strated, an outpatient, placebo-controlled study was conducted using a freeze-dried formulation to further evaluate its safety to its attenuation. First, wild-type V. cholerae C6709 was deleted at what was formerly termed the cholera toxin genetic and immunogenicity. element [8] , recently discovered to encode a filamentous bacteriophage, designated CTX-phage [9] . Next, the cholera toxin Materials and Methods B subunit gene, regulated by a V. cholerae heat-shock proInpatient study. Twelve community volunteers, aged 18-50 years, were recruited for the inpatient study using advertisements in a local newspaper. Inclusion criteria included being healthy, being willing to participate, and completing a training session Received 5 December 1996; revised 27 February 1997. designed to provide sufficient knowledge of the disease and the years, receipt of cholera vaccine, history of cholera infection, pre-D.O., K.M., and D.S. are employees of and own stock in the company that vious participation in a cholera or enterotoxigenic Escherichia coli owns the vaccine strain being studied. study, inability to pass the written examination on diarrhea, chol- Center, Johns Hopkins Hospital, and were randomized to receive ᭧ 1997 by The University of Chicago. All rights reserved. 0022-1899/97/7601-0026$02.00 either 10 9 or 10 7 cfu of the vaccine strain in a double-masked manner. On the day of admission, the volunteers drank their asconsistency in 24 h. They also submitted fecal specimens on days 3, 7, 10, 14, and 21 after immunization, using tubes of both PBS signed dose of vaccine with 100 mL of buffer (2.5 g of sodium bicarbonate and 1.65 g of ascorbic acid). Volunteers fasted for 60 and alkaline-peptone-water (APW) as transport media for the stool specimen. These media were found to preserve the vaccine strain min before and after the dose. All volunteers received active vaccine (i.e., none received placebo), but the clinical and laboratory most effectively during the inpatient study and were superior to Cary Blair transport medium for this purpose. Serum was obtained staff were masked as to the dose each volunteer received.
The volunteers were clinically monitored at least twice daily by before and 10 and 21 days after immunization. Laboratory procedures. Freshly harvested bacteria were prea study physician, vital signs were taken four times daily, and all stools were examined, graded, and weighed. Stool consistency was pared for the inpatient volunteers following a standard procedure. Briefly, a vial of frozen Peru-15 seed was thawed, 0.1 mL of the graded with a score from 1 to 5 as previously described [5] . Stool grades 1 and 2 were considered normal, while grades 3-5 were thawed culture was spread on a plate of Luria-Bertani agar, and the plate was incubated for 18 h at 30ЊC. After incubation, the considered loose or watery. Intake and output of fluids were measured. Diarrhea was defined as §2 stools of a consistency of §3 bacteria were harvested with 5 mL of 0.85% saline, and standard dilutions were prepared in saline. The optical density of the suspentotaling ú400 g or a single stool with a consistency of §3 totaling §300 g in 24 h. The first 2 stool specimens of each day from sion was determined and adjusted to produce a stock suspension having a predicted concentration of colony-forming units per millieach volunteer were cultured to detect excretion of the vaccine strain, using both quantitative and qualitative methods.
liter. The vaccine inoculum dose was verified by standard dilution and plate counts on mock vaccine doses that were made in parallel On day 6, all volunteers began taking doxycycline: 200 mg as a first dose, followed by 100 mg twice daily for 3 more days. The to those administered to the volunteers.
To identify the vaccine strain in the volunteer's feces during volunteers were discharged when their stools were negative for the inpatient study, the first 2 stools passed daily were cultured the vaccine strain. During the inpatient stay, volunteers were under quantitatively and qualitatively for V. cholerae in the Vaccine enteric (contact) precautions, and all feces were passed into disposTesting Unit laboratory. For qualitative cultures, fecal specimens able plastic containers for observation by study personnel. After were inoculated in Cary Blair transport medium and transported being weighed and sampled, feces were decontaminated by being to the laboratory. There they were plated directly onto TCBS (thiosoaked in disinfectant for 1 h, after which the stool was flushed sulfate, citrate, bile salts, sucrose) agar and also inoculated into down the toilet.
APW for subsequent plating onto TCBS agar. For quantitative Serum samples were collected before vaccination, on day 6 after cultures, 10-fold dilutions of stool were prepared in PBS, 100 mL vaccination (before starting antibiotic), and on days 14 and 28 was spread onto TCBS plates, and typical colonies were counted. after vaccination. Stool samples were collected on days 14 and 28
Plates were incubated at 35ЊC for 18-24 h. Colonies suspected during follow-up visits to evaluate the possibility of continued from the qualitative and quantitative plate cultures to be Peru-15 excretion of the vaccine strain.
were confirmed by oxidase and agglutination with V. cholerae O1 Outpatient study. Fifty healthy men and women, 18-50 years antiserum, and representative colonies were tested for motility old, were recruited to participate in the outpatient study, designed using a motility agar plate. to extend the inpatient studies by evaluating the same vaccine For the outpatient study, the two vials (PBS and APW) were strain when prepared in a lyophilized form. Recruitment for the both inoculated onto TCBS media (the APW after 6 h of incubaoutpatient study was primarily through University bulletins and tion). Quantitative cultures were not possible with the outpatient most volunteers were either students or employees of Johns Hopspecimens because the fecal samples were collected in transport kins University or Hospital. The same inclusions and exclusions broth. Again, colonies typical of V. cholerae were confirmed as were used for the outpatient study, but since this was the first Peru-15 using oxidase and agglutination tests and motility agar. outpatient study with this strain, potential volunteers were also By testing normal stools, to which known numbers of Peru-15 excluded if they were food handlers or had close contact with were added, these methods yielded positive results if the concentrachildren under age 5, immunosuppressed persons, or pregnant tion of bacteria was ú5 1 10 2 /g of stool. women.
Serum specimens were tested for vibriocidal antibody titer using Volunteers were randomized to receive either a 10 9 or 10 8 cfu an initial dilution of 1:10 and serial 2-fold dilutions of serum in dose or a placebo in a double-masked manner. The placebo cona standard microtiter plate [10] . The assay used an El Tor Inaba sisted of freeze-dried cryoprotectant buffer with 1% powdered strain (N16961) as the target strain, and the titer was expressed as skim milk, identical to that in which the vaccine strain was prethe reciprocal of the highest dilution yielding ''no growth'' in the pared. At the time of vaccination the lyophilized bacteria (or plawell. IgG antitoxin antibodies were measured by a microtiter cebo) were reconstituted in 1 mL of the buffer administration ELISA method [10] with 3-fold serial dilutions using 1:10 as the solution. Then either 1 or 0.1 mL of the vaccine was added to 100 initial dilution. The antitoxin titer shown is the reciprocal of the mL of the sodium bicarbonate-ascorbic acid buffer, and this was extrapolated dilution of serum that yielded 0.4 OD in the plate. given to the volunteer to drink. Each volunteer swallowed the dose All serologic assays were carried out in a blinded manner, and the while being observed by an investigator (J.S.). To protect the code to the study was not opened until after the laboratory assays masked code, some volunteers were assigned to 1 or 0.1 mL of were complete. placebo. Volunteers fasted for at least 1 h before and after immunization. group. The antitoxin GMTs increased by 4.1-and 4.6-fold for the 10 9 cfu and 10 8 cfu groups, respectively, on days 0, 10, and 21 (table 2) . The GMTs increased significantly in both 38.7ЊC the evening following the vaccination, and this was associated with chilly feelings but with no localized symptoms vaccine groups, with the peak titer being seen on day 21, but there was no apparent difference between the vaccine groups or physical findings. A blood culture and a complete blood count the evening of the fever were negative. The volunteer in antibody response. None of the placebo recipients had a significant rise in titer, and the GMT did not change in the felt well the next day and remained well throughout the remainder of the study. None of the inpatient volunteers complained placebo group. The vaccine strain was excreted in the feces of 66% (21/32) of loose stools, and none complained of abdominal cramps, nausea, vomiting, or other intestinal symptoms. On inspection of the volunteers receiving the vaccine, but it was not isolated from those receiving the placebo (table 3) . There was a trend of the stools however, loose stools (grade 3) were observed from 5 of the 12 volunteers, with amounts ranging from 261 for the vaccine to be excreted longer in those receiving 10 9 cfu, but this was not statistically significant. None of the fecal to 388 g in 24 h. None of these met a common definition of diarrhea ( §3 loose stools in 24 h). None of the volunteers had specimens were positive after day 10. Examination of the relation between fecal shedding of the a watery stool (grade 4 or 5).
Four of 6 volunteers receiving 10 9 cfu and 2 of 6 receiving vaccine strain and antibody responses revealed no clear relationship. Volunteers with negative fecal cultures had the same 10 7 cfu developed significant ( §4-fold) increases in vibriocidal antibodies; the geometric mean titer (GMT) rose 36-and 5-frequency and magnitude of vibriocidal and antitoxin responses as those with positive cultures. fold in the 10 9 and 10 7 cfu groups, respectively. Two volunteers in each group had at least a 2-fold rise in serum IgG antitoxin antibodies; the GMT rose 1.7-and 1.2-fold in the 10 9 and 10 7 Discussion cfu groups, respectively.
Four of 6 volunteers in the high-dose and 4 of 6 in the lowPeru-15 is a promising new live oral cholera vaccine. When a single dose of a reconstituted freeze-dried formulation of dose group excreted the vaccine strain in stool. Those receiving 10 9 cfu tended to have higher concentrations in the stool; all Peru-15 was administered in a manner similar to that appropriate for routine office practice, it was safe and highly immuvolunteers receiving this dose had peak concentrations ú10 3 cfu/g, while 2 of those receiving 10 7 had concentrations õ10 2 nogenic. The universal seroconversions among the outpatients receiving Peru-15 and the magnitude (fold rises) of the vibriocicfu/g. However, these differences were not significant. Peak concentrations were 10 6 cfu/g in both groups. Seven of the 8 dal responses were similar to those reported for CVD 103-HgR [11 -13], a live oral cholera vaccine licensed in Europe, volunteers who excreted vibrios still had positive stool cultures on day 6 when the antibiotic therapy was started. All recovered Canada, and South America. A true comparison would require including the two vaccine strains in the same study. Without isolates were nonmotile.
Outpatient study. Fifty volunteers received the vaccine or a challenge study, one cannot conclude that these serologic responses will be accompanied by high-grade long-lasting proa placebo in the outpatient study: 16 received 10 9 cfu, 16 received 10 8 cfu, and 18 received placebo. All volunteers comtection; however, past experience has shown that the development of vibriocidal antibodies has been accompanied by protecpleted their symptom diaries, all completed their assigned visits, and all submitted all of their fecal and serum specimens.
tion [5] , and the past trial with the vaccine using freshly prepared vaccine did suggest protection [7] . Surveillance for adverse events revealed no attributable side effects, though a few mild symptoms were reported by persons
The current study evaluated the strain first in inpatient volunteers in a clinical research ward, where the volunteers could who received vaccine as well as placebo as shown in prevent premature release of this new, genetically engineered unteers were generally associated with Johns Hopkins University, whereas the inpatient volunteers were recruited from the strain into the environment. Under these conditions, there were no serious adverse events, and the phenotype of the recovered community. Both groups were healthy as determined by a history, physical examination, and screening laboratory tests, but it strains remained unchanged. The fever in 1 inpatient volunteer remains unexplained and its relation to the vaccine is not is possible that differences existed between the groups. Similar proportions of volunteers excreted the vaccine strain in the known.
After the vaccine was found to be safe and genetically stable inpatient and outpatient studies, suggesting that a difference in colonization does not account for the differences in immune in volunteers, an outpatient study was carried out using a freeze-dried formulation. The freeze-dried vaccine was stored responses. frozen at 020ЊC and was reconstituted immediately before use
The antitoxin responses observed following immunization in the same buffer in which it was administered (bicarbonatewere less impressive than the vibriocidal responses. However, ascorbic acid buffer). All of the outpatient volunteers who ú60% of the outpatient volunteers developed an antitoxin IgG received this formulation developed a vibriocidal response but response and the GMT increased ú4-fold in the outpatient showed no evidence of attributable adverse events. A few minor groups receiving vaccine. This magnitude of increase in serum gastrointestinal complaints were reported in all groups with GMT is similar to that observed after two or three doses of similar frequencies, including the placebo group, suggesting the killed oral whole cell/B subunit (WC/BS) vaccines, though either that the buffer caused mild discomfort or that a certain the rate of responses is somewhat less [10, 14] . The WC/BS frequency of mild symptoms exist as ''background symptoms'' vaccine does protect against heat-labile strains of enterotoxiamong persons who are encouraged to report all symptoms. genic E. coli by way of antitoxic immunity for a few months Reasons for the more consistent serologic response in the [15] , so it is likely that Peru-15 may also protect to a degree outpatients compared with the inpatients is not known. The against this other enterotoxigenic infection. timing of collection of samples for serum was slightly different Our study did not include measures of local intestinal immuin the 2 groups. It is also possible that the freeze-dried form nity, such as intestinal lavage specimens or antibody secreting of the vaccine is more immunogenic, or alternatively, the volcells [16 -18] . While it is expected that an oral cholera vaccine unteers who participated in the outpatient study 
